Indaptus Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Indaptus Therapeutics, Inc. (INDP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 50.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 50.00K shares.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 25.00K shares, a 93.75% decline year-over-year.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 28.30K shares, a 96.62% decline from fiscal 2024.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 838.25K shares, a 96.89% increase from fiscal 2023.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 425.75K shares, a 31.49% decline from fiscal 2022.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 621.45K shares, a 41.91% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 50.00K shares 10-Q · filed 2026-08-13 | 75.00K shares derived: sum of 3 quarters · filed 2026-08-13 | 75.00K shares derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | 50.00K shares 10-Q · filed 2026-05-15 | 75.00K shares derived: sum of 2 quarters · filed 2026-05-15 | 75.00K shares derived: sum of 3 quarters · filed 2026-05-15 | ||
| 2025-12-31 | 25.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 25.00K shares derived: sum of 2 quarters · filed 2026-03-17 | 28.30K shares 10-K · filed 2026-03-17 | ||
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 3.30K shares 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 3.30K shares 10-Q · filed 2025-08-13 | ||||
| 2024-12-31 | 400.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 400.00K shares derived: sum of 2 quarters · filed 2025-03-13 | 492.50K shares derived: sum of 3 quarters · filed 2025-03-13 | 838.25K shares 10-K · filed 2025-03-13 | |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 92.50K shares derived: sum of 2 quarters · filed 2024-11-12 | 438.25K shares 10-Q · filed 2024-11-12 | 438.25K shares derived: sum of 4 quarters · filed 2024-11-12 | |
| 2024-06-30 | 92.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 438.25K shares 10-Q · filed 2024-08-12 | 438.25K shares derived: sum of 3 quarters · filed 2024-08-12 | 528.25K shares derived: sum of 4 quarters · filed 2024-08-12 | |
| 2024-03-31 | 345.75K shares 10-Q · filed 2024-05-08 | 345.75K shares derived: sum of 2 quarters · filed 2024-05-08 | 435.75K shares derived: sum of 3 quarters · filed 2024-05-08 | 515.75K shares derived: sum of 4 quarters · filed 2024-05-08 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 90.00K shares derived: sum of 2 quarters · filed 2024-03-13 | 170.00K shares derived: sum of 3 quarters · filed 2024-03-13 | 425.75K shares 10-K · filed 2024-03-13 | |
| 2023-09-30 | 90.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 170.00K shares derived: sum of 2 quarters · filed 2023-11-06 | 425.75K shares 10-Q · filed 2023-11-06 | 425.75K shares derived: sum of 4 quarters · filed 2023-11-06 | |
| 2023-06-30 | 80.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 335.75K shares 10-Q · filed 2023-08-14 | 335.75K shares derived: sum of 3 quarters · filed 2023-08-14 | 493.00K shares derived: sum of 4 quarters · filed 2023-08-14 | |
| 2023-03-31 | 255.75K shares 10-Q · filed 2023-05-11 | 255.75K shares derived: sum of 2 quarters · filed 2023-05-11 | 413.00K shares derived: sum of 3 quarters · filed 2023-05-11 | 438.00K shares derived: sum of 4 quarters · filed 2023-05-11 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | 157.25K shares derived: sum of 2 quarters · filed 2023-03-17 | 182.25K shares derived: sum of 3 quarters · filed 2023-03-17 | 621.45K shares 10-K · filed 2023-03-17 | |
| 2022-09-30 | 157.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 182.25K shares derived: sum of 2 quarters · filed 2022-11-10 | 621.45K shares 10-Q · filed 2022-11-10 | 641.45K shares derived: sum of 4 quarters · filed 2022-11-10 | |
| 2022-06-30 | 25.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 464.20K shares 10-Q · filed 2022-08-08 | 484.20K shares derived: sum of 3 quarters · filed 2022-08-08 | ||
| 2022-03-31 | 439.20K shares 10-Q · filed 2022-05-12 | 459.20K shares derived: sum of 2 quarters · filed 2022-05-12 | |||
| 2021-12-31 | 20.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | 1.07M shares 10-K · filed 2022-03-21 | |||
| 2021-09-30 | 1.05M shares 10-Q · filed 2021-11-15 | ||||
| 2021-08-04 | 1.05M shares 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |